Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer

Annals of Nuclear Medicine

Volumn 22, Issue 2, 2008, Pages 103-109

  Kitajima, Kazuhiro ^a   Murakami, Koji ^a   Yamasaki, Erena ^a   Hagiwara, Shingo ^a   Fukasawa, Ichio ^a   Inaba, Noriyuki ^a   Kaji, Yasushi ^a   Sugimura, Kazuro ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18F FDG; Endometrial cancer; PET CT; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 40149092662     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-007-0087-y     Document Type: Article

References (19)

1. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
2. Irvin WP, Rice LW, Berkowitz RS. Advances in the management of endometrial adenocarcinoma: a review. J Reprod Med 2002;47:173-190.
3. Kao MS. Management of recurrent endometrial cancer. Chang Gung Med J 2004;7:639-645.
4. Cherchi PL, Dessole S, Ruiu GA, Ambrosini G, Farina M, Capobianco G, et al. The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20:315-317.
5. Low RN, Sigeti JS. MR imaging of peritoneal disease: comparison of contrast-enhanced fast multiplanner spoiled gradient-recalled and spin-echo imaging. Am J Roentgenol 1994;163:1131-1140.
6. Sugiyama T, Nishida T, Ushijima K, Sato N, Kataoka A, Imaishi K, et al. Detection of lymph node metastasis in ovarian carcinoma and uterine corpus carcinoma by preoperative computerized or magnetic resonance imaging. J Obstet Gynaecol 1995;21:551-556.
7. Forstner R, Hricak H, Powell CB, Azizi L, Frankel SB, Stern JL. Ovarian cancer recurrence: value of MR imaging. Radiology 1995;196:1131-1140.
8. Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol 2000;95:692-696.
9. Topuz E, Aydiner A, Saip P, Eralp Y, Tas F, Salihoglu Y, et al. Correlation of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer. Eur J Gynaecol Oncol 2000;21:599-602.
10. Cook GJ, Maisery MN, Fogelman I. Normal variants, artifacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363-1379.
11. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003;23:315-340.
12. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-1379.
13. Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529-534.
14. Makhija S, Howden N, Edwards R, Kelley J, Townsend W, Meltzer C. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002;85:53-58.
15. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519-528.
16. Belhocine T, Debarsy C, Hustinx R, Willems-Foidart J. Usefulness of 18F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002;9:1132-1139.
17. Saga T, Higashi T, Ishimori T, Mameda M, Nakamoto Y, Mukai T, et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003;17:193-203.
18. Chao A, Chang TC, Ng KK, Hsueh S, Huang HJ, Chou HH, et al. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging 2006;33:36-44.
19. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-1019.